Changes in Cardiac Na(V)1.5 Expression, Function, and Acetylation by Pan-Histone Deacetylase Inhibitors

Qin Xu,Dakshesh Patel,Xian Zhang,Richard D. Veenstra

DOI: https://doi.org/10.1152/ajpheart.00156.2016

2016-01-01

Abstract:Histone deacetylase (HDAC) inhibitors are small molecule anticancer therapeutics that exhibit limiting cardiotoxicities including QT interval prolongation and life-threatening cardiac arrhythmias. Because the molecular mechanisms for HDAC inhibitor-induced cardiotoxicity are poorly understood, we performed whole cell patch voltage-clamp experiments to measure cardiac sodium currents (I-Na) from wild-type neonatal mouse ventricular or human-induced pluripotent stem cellderived cardiomyocytes treated with trichostatin A (TSA), vorinostat (VOR), or romidepsin (FK228). All three pan-HDAC inhibitors dose dependently decreased peak I-Na density and shifted the voltage activation curve 3-to 8-mV positive. Increases in late I-Na were not observed despite a moderate slowing of the inactivation rate at low activating potentials (< - 40 mV). Scn5a mRNA levels were not significantly altered but Na(V)1.5 protein levels were significantly reduced. Immunoprecipitation with anti-Na(V)1.5 and Western blotting with anti-acetyl-lysine antibodies indicated that Na(V)1.5 acetylation is increased in vivo after HDAC inhibition. FK228 inhibited total cardiac HDAC activity with two apparent IC(50)s of 5 nM and 1.75 mu M, consistent with previous findings with TSA and VOR. FK228 also decreased ventricular gap junction conductance (g(j)), again consistent with previous findings. We conclude that pan-HDAC inhibition reduces cardiac I-Na density and Na(V)1.5 protein levels without affecting late I-Na amplitude and, thus, probably does not contribute to the reported QT interval prolongation and arrhythmias associated with pan-HDAC inhibitor therapies. Conversely, reductions in g(j) may enhance the occurrence of triggered activity by limiting electrotonic inhibition and, combined with reduced I-Na, slow myocardial conduction and increase vulnerability to reentrant arrhythmias.